In contrast, a pooled clinical data analysis for empagliflozin (11) examining N = 8500 T2DM patients from 17 placebo-controlled Phase I to III trials plus six extension trials (study duration up to 104 weeks), found no increase in fracture incidence and no significant change in serum calcium, phosphate, magnesium, parathyroid hormone, alkaline phosphatase, or urinary N-telopeptide concentration among empagliflozin-treated subjects, perhaps suggesting drug-specific differences in ultimate skeletal impact (23). This evidence concerns the gene PTH and type 2 diabetes mellitus.